Sanofi has appointed David Meeker CEO of Genzyme, replacing Henri Termeer, effective 1 November 2011. He will report to Christopher Viehbacher, CEO of Sanofi and chair of Genzyme. Under Mr Meeker's leadership Genzyme plans to incorporate the rare disease business and the multiple sclerosis franchise. Mr Meeker has served at Genzyme since 1994, most recently as COO.
David Meeker will inherit CEO job at Genzyme
Sanofi has appointed David Meeker CEO of Genzyme, replacing Henri Termeer, effective 1 November 2011. He will report to Christopher Viehbacher, CEO of Sanofi and chair of Genzyme. Under Mr Meeker's leadership Genzyme plans to incorporate the rare disease business and the multiple sclerosis franchise. Mr Meeker has served at Genzyme since 1994, most recently as COO.
More from Neurological
- • By
GLP-1 receptor agonists could play a big role in tackling neurodegeneration and a new academic study has raised expectations of Novo Nordisk’s latest semaglutide Phase III results
- • By
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
- • By
An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.
- • By
As it posts third-quarter numbers that again reveal the decline of revenues from its multiple sclerosis portfolio, the US biotech major is entering into the hot area of targeted protein degradation to boost its immunology and neurology pipeline.
More from Therapeutic Category
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
